MultiCell Technologies' Proprietary Breakthrough Anti-Cancer Therapy Shown to Prevent Recurrence of Cancer.

Company's MCT-465 Drug Combined with Patented Immune-System Modulation Technology Prevents New Tumor Growth in Preclinical Animal Model

SAN DIEGO -- MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation technologies, has announced that the Company's proprietary anti-cancer technologies not only eradicated cancer in animal studies but also prevented the recurrence of the disease.

The research focused on a unique combination therapy based on MCET's MCT-465 drug candidate co-administered with IgNP, a proprietary MCET immune-modulation drug. It found that the Company's combination therapy not only destroyed cancerous tumors but conferred protection against new tumor growth, or recurrence of the disease.

"In cancer treatment, destroying the tumor is half the battle, while the other half is preventing the cancer from recurring," said Dr. Stephen Chang, Chief Executive Officer of MultiCell Technologies. "These findings are important because they demonstrate that our drug can prevent the cancer from returning. Preventing cancer from recurring in animal models is an important benchmark in developing new cancer therapeutics and toward prolonging life."

Specifically, the research examined the co-administration of MCT-465, a Toll-like Receptor (TLR) agonist and IgNP, the Company's patented antigen presenting immunoglobulin therapeutic.

"Previously we demonstrated conclusively that co-administration of MCT-465 with our patented antigen-presenting immunoglobulin therapeutic ('IgNP') completely destroyed tumors and prevented mortality," said Dr. Chang. "Now we have demonstrated that this same therapy prevents the recurrence of secondary cancers in animal models. Additionally, the T-cells from the immunized mice displayed a long-lasting, increased production of certain cytokines which are key players in the destruction of tumors."

The Company's scientists demonstrated that mice previously treated with the IgNP/MCT-465 combination therapy which demonstrated tumor remission, remained immune to the development of new cancers even when challenged with a new tumorigenic dose of homologous tumor cells. The challenged mice were completely protected against secondary cancers, whereas the control group of mice developed tumors with a 100% rate.

"Our work in this area was recently published in the Journal of Immunology, and we have filed several patents covering the technology," noted Dr. Chang.

MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious diseases, including multiple sclerosis, type-1 diabetes, influenza, and cancer.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system.

MultiCell's therapeutic pipeline includes drug candidates, some of which are in various advanced stages of human clinical trials. These therapies include:

* MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.

* MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.

* MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.

* MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT-465 in preclinical studies successfully eliminated certain types of tumors in animal models.

The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-465. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize MCT-465 as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.